FR940621-2-00060 FR940621-2-00039 4. (a) Ownership of tangible property as between Provider and Recipient is defined in Attachment A. (b) Recipient is free to file patent applications claiming inventions made by Recipient through the use of the Material but agrees to notify Provider upon filing a patent application claiming Modifications or uses of the Material. 5. (a) Except as expressly provided in this Agreement, no rights are provided to Recipient under any patents, patent applications, trade secrets or other proprietary rights of Provider. In particular, no rights are provided to use the Material or Modifications and any related patents of Provider for profit-making or commercial purposes, such as sale of the Material or Modifications, use in manufacturing, provision of a service to a third party in exchange for consideration (not including sponsored research activities except as provided for in 5(b). (b) If Recipient desires to use the Material or Modifications for such profit-making or commercial purposes, Recipient agrees, in advance of such use, to negotiate in good faith with Provider to establish the terms of a commercial license. It is understood by Recipient that Provider shall have no obligation to grant such a license to Recipient, and may grant exclusive or non-exclusive commercial licenses to others. 6. The provision of the Material to Recipient shall not alter any pre-existing right to the Material. If Provider has granted any rights to a third party (other than the customary rights granted to the Federal Government or non-profit foundations) which would affect Recipient, those rights will be identified by Provider in an implementing letter. 7. Any Material delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. Provider makes no representations and extends no warranties of any kind, either expressed or implied. There are no express or implied warranties of merchantability or fitness for a particular purpose, or that the use of the material will not infringe any patent, copyright, trademark, or other proprietary rights. 8. Except to the extent prohibited by law, Recipient assumes all liability for damages which may arise from its use, storage or disposal of the Material. Provider will not be liable to Recipient for any loss, claim or demand made by Recipient, or made against Recipient by any other party, due to or arising from the use of the Material by Recipient, except to the extent permitted by law when caused by the gross negligence or willful misconduct of Provider. 9. This agreement shall not be interpreted to prevent or delay publication of research findings resulting from the use of the Material or Modifications. Recipient's Scientist agrees to provide appropriate acknowledgement of the source of the Material in all publications. 10. Recipient agrees to use the Material in compliance with all applicable statutes and regulations, including Public Health Service and NIH regulations and guidelines such as, for example, those relating to research involving the use of animals or recombinant DNA. 11. (a) This Agreement will terminate on the earliest of the following dates: (1) when the Material becomes generally available from third parties, for example, through reagent catalogs or public depositories, or (2) on completion of Recipient's current research with the Material, or (3) on thirty (30) days written notice by either party to the other, or (4) on the date specified in an implementing letter. Paragraphs 7 and 8 shall survive termination. (b) If termination should occur under 11(a)(1), Recipient shall be bound to the Provider by the least restrictive terms applicable to Material obtained from the then-available sources. (c) Except as provided in 11.(d) below, on termination of this Agreement under 11.(a)(2), (3), or (4) above, Recipient will discontinue its use of the Material and will, upon direction of Provider, return or destroy any remaining Material. Recipient will also either destroy Modifications or remain bound by the terms of paragraphs 4 and 5 as they apply to Modifications. (d) In the event Provider terminates this Agreement under 11.(a)(3) other than for breach of this Agreement or with cause such as an imminent health risk or patent infringement, Provider will defer the effective date of termination for a period of up to one year, upon request from Recipient, to permit completion of research in progress. 12. The Material is provided free or with a fee solely to reimburse Provider for its distribution costs. If a fee is requested, it will be enumerated in an implementing letter.
